Huiskamp Laura F J, Chargi Najiba, Devriese Lot A, May Anne M, Huitema Alwin D R, de Bree Remco
Department of Head and Neck Surgical Oncology, UMC Utrecht Cancer Center, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
J Clin Med. 2020 Nov 23;9(11):3780. doi: 10.3390/jcm9113780.
Low skeletal muscle mass (LSMM) is increasingly recognized for its predictive value for adverse events in cancer patients. In specific, the predictive value of LSMM has been demonstrated for anti-cancer drug toxicity in a variety of cancer types and anti-cancer drugs. However, due to the limited sample size and study populations focused on a single cancer type, an overall predictive value of LSMM for anti-cancer drug toxicity remains unknown. Therefore, this review aims to provide a comprehensive overview of the predictive value of LSMM and perform a meta-analysis to analyse the overall effect. A systematic search was conducted of MEDLINE, Scopus, EMBASE, and Cochrane. Inclusion criteria were skeletal muscle mass (SMM) evaluated with computed tomography (CT) or magnetic resonance imaging (MRI), articles published in English, SMM studied in humans, SMM measurement normalized for height, and patients did not receive an intervention to treat or prevent LSMM. A meta-analysis was performed using a random-effects model and expressed in odds ratio (OR) with 95% confidence interval (CI). Heterogeneity was assessed using χ and I statistics. The search yielded 907 studies. 31 studies were included in the systematic review. Sample sizes ranged from 21 to 414 patients. The occurrence of LSMM ranged from 12.2% to 89.0%. The most frequently studied cancer types were oesophageal, renal, colorectal, breast, and head and neck cancer. Patients with LSMM had a higher risk of severe toxicity (OR 4.08; 95% CI 2.48-6.70; < 0.001) and dose-limiting toxicity (OR 2.24; 95% CI 1.28-3.92; < 0.001) compared to patients without LSMM. To conclude, the predictive value of LSMM for anti-cancer drug toxicity can be observed across cancer types. This information increases the need for further research into interventions that could treat LSMM as well as the possibility to adapt treatment regimens based on the presence of LSMM.
低骨骼肌质量(LSMM)对癌症患者不良事件的预测价值日益受到认可。具体而言,LSMM在多种癌症类型和抗癌药物中对抗癌药物毒性的预测价值已得到证实。然而,由于样本量有限且研究人群集中于单一癌症类型,LSMM对抗癌药物毒性的总体预测价值仍不明确。因此,本综述旨在全面概述LSMM的预测价值,并进行荟萃分析以分析总体效应。我们对MEDLINE、Scopus、EMBASE和Cochrane进行了系统检索。纳入标准包括通过计算机断层扫描(CT)或磁共振成像(MRI)评估的骨骼肌质量(SMM)、以英文发表的文章、在人类中研究的SMM、针对身高进行标准化的SMM测量,以及患者未接受治疗或预防LSMM的干预措施。使用随机效应模型进行荟萃分析,并以比值比(OR)和95%置信区间(CI)表示。使用χ²和I²统计量评估异质性。检索共获得907项研究。31项研究纳入系统评价。样本量从21例至414例患者不等。LSMM的发生率在12.2%至89.0%之间。研究最频繁的癌症类型为食管癌、肾癌、结直肠癌、乳腺癌和头颈癌。与无LSMM的患者相比,有LSMM的患者发生严重毒性的风险更高(OR 4.08;95% CI 2.48 - 6.70;P < 0.001)以及剂量限制性毒性的风险更高(OR 2.24;95% CI 1.28 - 3.92;P < 0.001)。总之,LSMM对抗癌药物毒性的预测价值在各种癌症类型中均可观察到。这一信息增加了对能够治疗LSMM的干预措施进行进一步研究的必要性,以及根据LSMM的存在调整治疗方案的可能性。